D-0249-2019 Class III Terminated
FDA drug recall D-0249-2019 was initiated by Amerigen Pharmaceuticals Inc. on Oct 5, 2018 and is designated Class III. Reason for recall: Failed dissolution specifications: Out-of-Specification dissolution results obtained during stability testing. The recall status is terminated (terminated Sep 30, 2019). Affected quantity: 5,232 bottles: a) 4,146 bottles; b) 1,086 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 24, 2018
- Initiation Date
- Oct 5, 2018
- Termination Date
- Sep 30, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 5,232 bottles: a) 4,146 bottles; b) 1,086 bottles
Product description
Temozolomide capsules, 20 mg, packaged in a) 5-count bottle(NCD 43975-253-05), b) 14-count bottle (NDC 43975-253-14), Rx only, Mfd. by: Stason Pharmaceuticals, Inc., Irvine, CA 92618, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ 07071.
Reason for recall
Failed dissolution specifications: Out-of-Specification dissolution results obtained during stability testing.
Distribution pattern
Product was distributed U.S. nationwide.
Code information
Lot #: a) 17F058A, Exp 6/19; b) 17F058B, Exp 6/19
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0249-2019
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026